SG Americas Securities LLC grew its position in TransMedics Group, Inc. (NASDAQ: TMDX) by 125.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,725 shares of the company's stock after buying an additional 8,762 shares during the quarter. SG Americas Securities

TransMedics Group (NASDAQ: TMDX - Get Free Report) and WORK Medical Technology Group (NASDAQ: WOK - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings. Earnings and Valuation This table compares

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.

Disaboom (OTCMKTS:MEDH - Get Free Report) and TransMedics Group (NASDAQ: TMDX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Profitability This table compares Disaboom and TransMedics Group's net

TransMedics Group (NASDAQ: TMDX) CEO Waleed Hassanein and CFO Gerardo Hernandez-Omana provided updates on the company's strategy, clinical trial planning, and operational initiatives during a fireside chat hosted by Oppenheimer senior medical devices analyst Suraj Kalia. Expanding TransMedics' role in the U.S. transplant ecosystem Hassanein said TransMedics began as a medical device company and emphasized the

TransMedics is positioned for accelerating growth, with revenue expected to expand around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. TMDX is over the crest of its capex cycle, with investment pressures expected to ease, supporting margin expansion toward a 30% target by 2028. Despite a weak balance sheet and potential for 15% shareholder dilution in 2026, I remain bullish as long as revenue growth stays above 20% y/y.

ArrowMark Colorado Holdings LLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ: TMDX) by 54.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 313,125 shares of the company's stock after purchasing an additional 109,830 shares during the quarter. ArrowMark

TransMedics has transitioned into a fundamentally strong, profitable growth story with reduced volatility and clear operational leverage. TMDX delivered a robust Q4, exceeding revenue and earnings estimates, with 32% Y/Y growth and expanding operating margins by over 610 bps. Management guides for 20-25% revenue growth in 2026, with Liver segment dominance and significant upside potential from Heart, Lung, and Kidney programs.

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.